Pharmadrug Inc (CSE:PHRX)

0.0050 UNCHANGED

Delayed Quote Updated: 9:30 AM EST, Nov 3, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	0.0050
Bid (Size)	0.0050 (988,000)
Ask (Size)	0.0100 (1,467,000)
Prev. Close	0.0050
Today's Range	0.0050 - 0.0050
52wk Range	0.0050 - 0.0250
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

May 13, 2026

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a...

Via Newsfile

PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins

August 21, 2024

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Performance

52-Week Range 80.0% below 52-week high

0.0050

0.0152W Low 0.0352W High

Pharmadrug Inc (PHRX) traded between $0.01 and $0.03 over the past 52 weeks and last traded at $0.01, 80.0% below its 52-week high.

Past 12 Months

N/A

-66.7%

-75.0%

6M -$0.01

YTD -$0.01

1Y -$0.01

PHRX was -75.0% over the past year, -66.7% over six months, -66.7% year to date.

12 Months vs Market

PHRX

-75.0%

DIA

+9.2%

SPY

+10.4%

QQQ

+8.4%

IWM

+14.0%

Over the past 12 months PHRX returned -75.0% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity

554.6K

188.6K

106.0K

102.5K

YTD

90.9K

93.0K

PHRX's 3-month average daily volume is 106.0K.

More News

PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

August 19, 2024

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

May 15, 2024

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

May 01, 2024

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

February 21, 2024

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Biotech Veteran David Kideckel Joins the Board of PharmaDrug

August 30, 2021

Via Newsfile

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

August 25, 2021

Via Newsfile

PharmaDrug Announces Appointment of Auditor

August 06, 2021

Via Newsfile

PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease

August 05, 2021

Via Newsfile

Frequently Asked Questions

Is Pharmadrug Inc publicly traded?

Yes, Pharmadrug Inc is publicly traded.

What exchange does Pharmadrug Inc trade on?

Pharmadrug Inc trades on the Canadian Securities Exchange

What is the ticker symbol for Pharmadrug Inc?

The ticker symbol for Pharmadrug Inc is PHRX on the Canadian Securities Exchange

What is the current price of Pharmadrug Inc?

The current price of Pharmadrug Inc is 0.0050

When was Pharmadrug Inc last traded?

The last trade of Pharmadrug Inc was at 11/03/26 09:30 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.